OMass Therapeutics
OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.
$310MSeries C
ParticipantSV
Sanofi Ventures
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
- Rounds participated in
- 8
- Confirmed lead rounds
- 0 7 roles undisclosed
- New companies
- 8 First participation on record · 0 follow-on
- Funding in participating rounds
- $1.2B 8 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
8 in this selectionAbcuro
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
$66MSeries D
Role not disclosedEpicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedQuantHealth
AI-driven platform that simulates clinical trials to predict outcomes before patient enrollment
$45MSeries B
Role not disclosedAdvanCell
AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.
$315MSeries D
Role not disclosedDraig Therapeutics
Draig Therapeutics develops neuropsychiatric medicines.
$65MSeries B
Role not disclosedBionyra Pharma
Bionyra Pharma develops biologic therapies for severe immunological and inflammatory diseases.
$165MSeries A
Role not disclosedKorsana Biosciences
Develops therapies for neurodegenerative diseases.
$175MSeries A
Role not disclosed